News
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
2h
Everyday Health on MSNFDA Approves a ‘Game-Changing’ Twice-a-Year HIV Prevention ShotThe new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.
The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...
The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily ...
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.
How an Indian contract manufacturer will establish a biotech foothold in the U.S.
The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...
Dailymotion on MSN9h
US FDA approves Gilead’s twice-yearly injection for HIV preventionThe US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for ...
A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More pharmaceutical news is about Dupixent, GLP-1 results, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results